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Abstract
Background: Methylenetetrahydrofolate reductase (MTHFR), a critical enzyme in folate metabolism is involved in
DNA synthesis, DNA repair and DNA methylation. The functional polymorphism of MTHFR gene, C677T has been
shown to impact various diseases and implicated as a risk factor for the development of various neurodegenerative
disorders including glaucoma.
Methods: We investigated MTHFR C677T genotypes and alleles frequencies in primary glaucoma [primary open angle
glaucoma (POAG) and primary angle closure glaucoma (PACG)] patients and matched healthy controls in a case-control
study. Two hundred ten primary glaucoma cases were studied for MTHFR C677T polymorphism and compared with 280
controls taken from the healthy population, employing the polymerase chain reaction-restriction fragment length
polymorphism technique (PCR-RFLP). The MTHFR gene was amplified using specific primers. The PCR products (294 bp)
was subsequently digested with HinfI (New England Biolabs) at 37 °C for 12 h, separated by electrophoresis on 2 %
agarose gels, and visualized with ethidium bromide staining. The restriction digestion yielded 168 and 126 bp fragments
for TT, 294, 168 and 126 bp fragments for CT and undigested PCR product 294 bp indicating CC genotype.
Results: We found the frequency of the genotypes and alleles of MTHFR C677T differ significantly between cases and
controls. The frequencies of allele T and genotype CT were significantly higher while the frequencies of allele C and
genotype CC were lower in primary glaucoma patients as compared to controls (p <0.05). Upon stratification of our
results into POAG and PACG, significantly higher frequencies of allele T (19.44 %) and genotype CT (38.89 %) were found
in POAG patients compared to controls (12.5 % and 25 % respectively). The frequencies of alleles and genotypes were
almost similar in PACG and controls (p = 0.8).
Conclusion: This study indicates that the allele T and genotype CT of MTHFR C677T polymorphism are significantly
associated with POAG while allele C and CC genotype may be protective for it. We conclude that the MTHFR C677T
polymorphism increases the risk for POAG development in Saudi population and can be a genetic marker however,
further studies are needed with multiple-ethnic populations affected with POAG to strengthen these findings.
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Background
Glaucoma is the second leading cause of blindness
worldwide. It is a relatively common eye disease charac-
terized by the pathological loss of retinal ganglion cells
resulting into progressive loss of sight and related
changes in the retinal nerve fiber layer and optic nerve
head [1]. Glaucoma affects 70 million people worldwide
and by the year 2020, this number is estimated to rise to
around 79.6 million [2]. Glaucoma can be classified as
primary or secondary based on the etiology and aqueous
humor dynamics [3]. Primary glaucoma (PG) is one of
the most common optic neuropathies and further classi-
fied as primary open angle glaucoma (POAG) and pri-
mary angle closure glaucoma (PACG) on the basis of
gonioscopy (anterior chamber anatomy) and their spe-
cific etiology.
Increased levels of homocysteine in plasma, serum and
tear have been found in patients with POAG, PACG and
pseudoexfoliative glaucoma [4–11]. The methylenetetra-
hydrofolate reductase (MTHFR) C677T (rs1801133) is
missense variation, located in exon of the MTHFR gene
on chromosome 1 and also known as Ala222Val or
A222V. MTHFR C677T polymorphism leads to an in-
crease in thermolability and reduced activity of the
MTHFR enzyme [12]. This reduction in enzymatic activity
of MTHFR ultimately leads to the elevation of homocyst-
eine levels in plasma [13]. MTHFR (EC1.5.1.20), being a
crucial enzyme in the pathway, diverts folate content
towards homocysteine remethylation. This enzyme cat-
alyzes reduction of 5,10-methylenetetrahydrofolate to
5-methyltetrahydrofolate, which acts as methyl donor
for remethylation of homocysteine to methionine [13].
The C677T polymorphism in the MTHFR gene causes
reduction in the activity of a thermolabile form of
MTHFR which is the most common genetic factor for
moderate hyperhomocysteinemia. The prevalence of
MTHFR C677T polymorphism has been reported to be
high in POAG patients [4, 14, 15]. However, earlier re-
ports on the association between MTHFR C677T poly-
morphism and glaucoma risk are inconclusive and
conflicting [6, 7, 16–20]. Saudi population being a closed
and isolated society with high rate of consanguinity (in-
breeding) is ideal for such genetic association studies. So
we decided to analyze any possible association between
MTFHR C677T polymorphism and PG (POAG and
PACG) in a cohort of Saudi population.
Methods
Subjects
The present study was undertaken to analyze 490 Saudi
subjects for the frequency of allele and genotype of
MTHFR C677T polymorphism. The sample size was calcu-
lated online (http://sampsize.sourceforge.net/iface/s3.html).
Initially we recruited 300 sample each for patient and
control group but after applying inclusion and exclusion
criteria only 210 patients and 280 controls were found suit-
able for inclusion in the study. A total of 210 unrelated
Saudi patients with PG including POAG (n = 144) and
PACG (n = 66) were recruited from ophthalmology clinic
of the Prince Sultan Military Medical City (PSMMC) Saudi
Arabia. The demographic characteristics of patients and
healthy controls are summarized in Table 1. Males (106)
and females (104), aged 30-78 years (mean ± SD: 58 ± 14.4)
constituted the patient group while 280 unrelated healthy
Saudi subjects of same ethnicity, aged 30 - 78 years
(mean ± SD: 56 ± 11.6) were recruited as controls. The
Table 1 Demographic characteristics of patient and controls
Primary glaucoma patients (210)
Age (years)
Range 30-78










Primary open angle glaucoma (POAG) (144)
Age (years)
Range 30-78




Primary angle closure glaucoma (PACG) (66)
Age (years)
Range 32-74
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PG patients were diagnosed on the basis of clinical ob-
servation as described earlier [21, 22]. Patients with
confirmed diagnosis of PACG or POAG free from any
other systemic and autoimmune diseases were selected
for this study. General inclusion criteria included ability
and willingness to provide informed consent, participants
may be male or female of age not less than 30 years. The
subjects with the diagnosis or history of any secondary
glaucoma, ocular trauma or significant use of systemic or
ocular glucocorticoids were excluded.
Patients with history of other ocular or neurologic dis-
ease or surgery that causes visual loss, systemic diseases
[lupus, Graves, cancer (within the last 5 years), AIDS,
other] that cause visual loss, or with history of ambly-
opia were also excluded. Patients with signs of intracra-
nial disease were also excluded. Professionally trained
glaucoma specialists reviewed medical records for all
cases and control subjects. Additionally all the control
subjects were examined by an ophthalmologist for docu-
mentation of cup-to-disc ratio, and any history of glau-
coma, elevated IOP, or optic nerve abnormality. Controls
with history of any systemic or autoimmune disease were
excluded.
The blood samples were collected and stored at -80 °C.
DNA was extracted using standard technique. The study
protocol was approved by the ethical committee of the
Prince Sultan Military Medical City (PSMMC) Riyadh,
Saudi Arabia (via # 318/2013 dated 24.4.2013) and written
informed consent was obtained from all participants.
Genotyping
Detection of the genotypes/alleles of MTHFR C677T
polymorphism was performed with PCR amplification
using a set of primers. The PCR was performed follow-
ing the protocol as described elsewhere [6]. The PCR
products (294 bp) were subsequently digested with HinfI
at 37 °C for 12 h, separated by electrophoresis on 2 %
agarose gels, and visualized with ethidium bromide
staining. The restriction digestion yields 168 and 126 bp
fragments for TT, 294, 168 and 126 bp fragments for CT
and undigested PCR product 294 bp indicating CC
genotype. For quality control the genotyping was re-
peated for 25 % of the random blind samples and results
were compared. The positive and negative controls were
also used in the PCR.
Statistical analysis
The genotyping results were analyzed and frequencies of
alleles and genotypes were calculated. Hardy-Weinberg
Equilibrium Calculator for 2 Alleles (http//www.had2
know.com/academics/hardy-weinberg-equilibrium-calcu-
lator-2alleles.html) was used to calculate Hardy-Weinberg
equilibrium. The differences in the frequencies of alleles
and genotypes between patients and controls were
analyzed by the Fisher’s exact test using the CalcFisher
software [23]. P values ≤ 0.05 were considered significant.
The strength of the association of disease with respect to a
particular allele/genotype is expressed by odd ratio inter-
preted as relative risk (RR) following the Woolf ’s method
as out lined by Schallreuter et al. [24]. The hypothetical
genetic component of the disease, etiologic fraction (EF)
and the hypothetical protective effect of one specific allele/
genotype for the disease, preventive fraction (PF) were cal-
culated following formula given by Svejgaard et al. [25] as
described in details in our earlier publication [22].
Results
The results of the genotypes and alleles distribution of
MTHFR C677T polymorphism in PG and controls are
summarized in Tables 2, 3, 4, 5. The single nucleotide
polymorphism in the MTHFR gene (rs1801133) was in
Hardy–Weinberg equilibrium for patients while not in
controls possibly due to high consanguinity. The fre-
quency of CT genotype was significantly higher (34.76 %
vs 25 %, p = 0.02) while the frequency of CC genotype
was lower (65.24 % vs 75 %, p = 0.02) in primary glau-
coma patients as compared to controls. Genotype TT
was absent both in the patients and controls groups.
Frequency of allele T was found to be significantly
higher while that of allele C was lower in PG patient
than controls (P = 0.03). Upon stratification of PG pa-
tients gender vise, no significant difference was found in
distribution of alleles and genotypes of MTHFR C677T
polymorphisms between male and female patients
(Table 3).
The genotyping results after stratification into POAG
and PACG and comparison with that of control group
are summarized in Tables 4 and 5. The frequencies of
genotype CT and allele T were significantly higher (p =
0.003, p = 0.008 respectively) in POAG as compared to
controls. While the frequencies of genotype CC and al-
lele C were significantly lower in POAG as compared to
controls (Table 4). On the other hand there was no sig-
nificant difference in the frequencies of both the alleles
and genotype between PACG and controls (p = 0.88).
Table 2 Genotype and allele frequencies of MTHFR (C677T)
variants in primary glaucoma patients and matched controls
Genotype/
allele
PG (N= 210) Control (N= 280) p-value RR EFb/PF
N % N %
CC 137 65.24 210 75.00 0.02a 0.63 0.194
CT 73 34.76 70 25.00 0.02a 1.60 0.191b
TT 0 0 0 - - - -
C-allele 347 82.62 490 87.50 0.03a 0.68 0.152
T-allele 73 17.38 70 12.50 0.03a 1.47 0.163b
N number of subjects, EF etiological fraction, PF preventive fraction
astatistically significant
bdata for EF
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The frequency distribution of alleles and genotypes of
MTHFR C677T in POAG and PACG shows similar pat-
tern and no significant difference could be noticed in
the frequencies of alleles and genotypes between PACG
and POAG. The results of repeated genotyping for 25 %
of the random blind samples on comparison with earlier
results indicted 100 % success rate. Genotype distribu-
tion of MTHFR C677T polymorphism in different
healthy population worldwide is summarized in Table 6
which clearly indicates ethnic variations.
Discussion
Results of the present study revealed significant differ-
ences in the frequencies of alleles and genotypes of
MTHFR C677T polymorphism between PG patients and
controls (Table 1). The significantly higher frequencies
of genotype CT and allele T in PG patients as compared
to controls indicated that the genotype CT and allele T
are associated with susceptibility to the PG (RR = 1.60,
EF = 0.19 and RR = 1.47, EF = 0.16 respectively). The
higher frequency of the T allele and predominance of
CT genotypes in PG patients in comparison with
matched controls suggested that allele T carriers are at a
higher risk of developing PG in Saudi population. The
genotype CC and allele C being higher in controls indi-
cated their protective nature for PG (RR = 0.63, PF = 0.19
and RR = 0.68, PF = 0.15 respectively). In gender wise
analysis, the genotype and allelic frequencies did not dif-
fer significantly between males and females indicating
that the distribution of alleles/ genotypes of MTHFR
C677T is not affected by any specific gender.
Further, stratification of results into PAOG and PACG,
revealed that the frequency distribution of alleles and ge-
notypes differed in two types of glaucoma. The higher
frequency of CT genotype and allele T in POAG indi-
cated that the genotype CT and allele T of MTHFR
C677T polymorphism might be associated with suscepti-
bility risk of POAG (RR = 1.91, EF = 0.211) while the de-
creased frequency of genotype CC in POAG as compared
to controls indicated that genotype CC may be resistant to
POAG in Saudis. Our results are in agreement with the
earlier findings which reported similar association be-
tween MTHFR C677T polymorphism and POAG in Ger-
man and Indian patients [4, 14, 15]. Similarly MTHFR
C677T polymorphism has also been reported as a genetic
risk factor of normal tension glaucoma (NTG) in the Ko-
rean population [20].
A significant associations between MTHFR C677T
polymorphism and POAG was suggested recently and a
meta-analysis indicated that the T allele or TT genotype
might increase the risk of POAG [26]. However, the
need for further studies with POAG patients using large
sample-size from multiple ethnicity has been empha-
sized to reach any definite conclusion.
On the other hand, several other studies suggested that
MTHFR C677T polymorphism itself is not a major risk fac-
tor [10, 27] as these studies could not find any significant
association with susceptibility risk of POAG in Japanese
[28], Austrian [16], Swedish [18], Pakistani [6], Iranian [29],
Mexican [30] and Greek populations [13].
Our results also indicated a lack of association be-
tween the MTHFR C677T polymorphism and PACG in
Saudi population as the frequencies of allele and geno-
types were almost similar in PACG and control subjects
(p = 0.88, Table 4). Similar to our findings, no association
of MTHFR C677T polymorphism has been found with
the susceptibility to PACG in Nepalese and Australian
[31], and Indian [15]. Contrary to these findings one re-
port from Pakistan indicates that the MTHFR C677T
polymorphism is associated with PACG. From the
Table 3 Genotype and allele frequencies of MTHFR (C677T)
variants in male and female primary glaucoma patients
Genotype/allele Male (106) Female (104) p-value
N % N %
CC 67 63.21 70 67.31 0.56
CT 39 36.79 34 32.69 0.56
TT 0 - 0 - -
C-allele 173 81.60 174 83.65 0.60
T-allele 39 18.40 34 16.35 0.60
N number of subjects
Table 4 Genotype and allele frequencies of MTHFR (C677T)
variants in POAG patients and matched controls
Genotype/
allele
POAG (N= 144) Control (280) P- value RR EFb/PF
N % N %
CC 88 61.11 210 75.00 0.003a 0.52 0.214
CT 56 38.89 70 25.00 0.003a 1.91 0.211b
TT 0 - 0 - - - -
C-allele 232 80.56 490 87.50 0.008a 0.59 0.182
T-allele 56 19.44 70 12.50 0.008a 1.69 0.181b
N number of subjects, EF etiological fraction, PF preventive fraction
astatistically significant
bdata for EF
Table 5 Genotype and allele frequencies of MTHFR (C677T)
variants in PACG patients and matched controls
Genotype/
allele
PACG (N= 66) Control (280) P- value RR EFa/PF
N % N %
CC 49 74.24 210 75.00 0.87 0.961 0.007
CT 17 25.76 70 25.00 0.87 1.041 0.007a
TT 0 - 0 - - -
C-allele 115 87.12 490 87.50 0.88 0.966 0.171
T-allele 17 12.88 70 12.50 0.88 1.0347 0.170a
N number of subjects, EF etiological fraction, PF preventive fraction
adata for EF
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available data it is evident that the prevalence of MTHFR
C677T polymorphism varies in different ethnic healthy
populations and also among the different types of glau-
coma. The frequencies of TT genotype vary from 0 to
28 %, except in Mexican population where it is quite
high (52 %), those of CT genotype from (2.4-53 %) and
CC genotype from 23-97 % in various populations
worldwide (Table 6). Similar to our finding two reports
one each from Pakistan and Turkey indicates absence of
TT genotype in healthy cohort. The ethnic variations in
Table 6 Genotype distribution of MTHFR C677T polymorphism in different healthy populations
Population/group studied Sample number Genotype frequencies % CC CT TT Reference
Saudis 280 75 25 0 Present study
American Whites 300 47.33 42.00 10.67 [45]
American Blacks 298 77.52 19.80 2.68 [45]
Australian 288 50.69 41.32 7.99 [45]
Austrian Caucasian 211 49.76 40.76 9.48 [16]
British Caucasian 58 46.55 46.55 6.90 [46]
Canadian whites 240 56.67 37.50 5.83 [45]
Chinese 381 57.74 30.71 11.55 [47]
Chinese 878 23 49.1 27.9 [48]
Colombian 152 34.45 52.55 13.0 [49]
Dutch 188 51.60 42.02 6.38 [45]
Egyptian 149 76.50 20.10 3.40 [50]
Finish 545 53.76 42.20 4.04 [45]
French 178 40.45 47.75 11.80 [45]
German 71 63 34 3 [14]
Greek 135 30 53.85 16.15 [51]
Han Chinese North 643 31.26 48.99 19.75 [45]
Han Chinese South 430 29 53 8.1 [45]
Indian 173 79.19 19.65 1.16 [15]
Indian 70 71.43 25.71 2.86 [52]
Indian 100 69 26 5 [53]
Iranian 90 58.89 36.67 4.44 [29]
Iranian females 116 54.3 37.1 8.6 [54]
Israeli 210 57.14 34.29 8.57 [45]
Italian whites 385 33.25 51.43 15.32 [45]
Japanese 106 45.3 36.8 17.9 [28]
Jordanian 150 52.77 34.53 12.70 [55]
Kashmiri 160 75.6 16.9 7.5 [56]
Korean 100 31 50 19 [20]
Mexican Nahuas 135 5.18 42.97 51.85 [57]
Mexican Mixtecas 124 9.7 40.3 50 [57]
Mexican Mestizas 196 16.8 44.4 38.8 [57]
Pakistani Pathan 70 76 23 1 [6]
Pakistani Punjabi 73 66 34 0
Pakistani 70 81.43 18.57 0 [58]
Russian 587 53.15 39.86 6.99 [45]
Spanish whites 601 44.09 44.09 11.82 [45]
Turkish 100 51 43 6 [59]
Turkish 212 97.6 2.4 0 [60]
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the distribution of alleles and genotype of MTHFR poly-
morphism in various populations and types of glaucoma
might have lead to differences in the findings.
The result of this study also showed complete absence
of homozygous genotype (TT) in our control and patient
groups. The frequency of heterozygous genotype CT
was 25 % and that of homozygous CC 75 % in Saudi
healthy population. Global studies on distribution of ge-
notypes of MTHFR C677T in healthy population have
shown highly significant variations in genotype frequen-
cies of TT, CT and CC (Table 6). The reason for the dis-
similar findings in different populations is not clear and
may reflect ethical differences/ geographical variations in
the genotype frequencies. Chiras et al. [32] also reported
variable frequency especially of genotype TT in popula-
tions from different geographic areas. The highest fre-
quency TT genotype of MTHFR C677T was found in
Mexico and the lowest in middle east, African coun-
tries, India and Pakistan. Therefore, it is important to
pay special attention on genetic association studies in
ethnic groups like Saudi Arabians that have remained
isolated from the rest of the world populations and has
retained their own cultural characteristics, lifestyle, and
traditions.
The MTHFR C677T polymorphism influences homo-
cysteine metabolism and hyperhomocysteinemia has
been reported in glaucoma patients [4–11]. The MTHFR
C677T polymorphism causes an alanine > valine amino
acid substitution, which influences the activity of
MTHFR enzyme. As a results of this polymorphism 55–
65 % loss in enzyme activity has been observed in indi-
viduals who are homozygous for the mutation (TT car-
riers), while in the case of heterozygotes (CT carriers)
there is a 25 % loss in activity compared to CC homozy-
gous normal individuals [13, 33]. This reduced activity
of MTHFR leads to hyperhomocysteinemia. The signifi-
cantly higher frequency of genotype CT in our POAG
patients as compared to controls might have resulted in
moderate hyperhomocysteinaemia. Although the exact
biologic role of hyperhomocysteinemia in glaucoma is
not clear yet, however it has been linked to other vascu-
lar diseases [34] and reported to cause dysregulation of
matrix metalloproteinases and their inhibitors [35]. The
dysregulation of matrix metalloproteinases has been im-
plicated in the pathogenesis of glaucoma [36]. Homocyst-
eine can also induce vascular injuries [37], alterations in
the extracellular matrix [38], and neuronal cell death by
inducing apoptosis or excitotoxicity [39, 40]. Moreover,
hyperhomocysteinemia has been shown to be involved in
the structural remodeling of connective tissues [41].
Hyperhomocysteinemia induced by the MTHFR C677T
polymorphism has been linked with neuronal cell death of
retinal ganglion cells (RGC), a characteristic feature of
glaucoma [15]. Despite the clinical heterogeneity, all forms
of glaucoma ultimately result in death of retinal ganglion
cells (RGC) in the optic nerve. Homocysteine has been re-
ported to induce apoptotic cell death of RGCs [15, 40]
and also exerts gliotoxic effects, thus representing a risk
factor for POAG [42]. Apoptotic death of RGCs in glau-
coma has been supported by various earlier molecular
studies [43, 44].
Our results indicate a significant association of MTHFR
C677T with POAG but not with PACG in Saudi popula-
tion suggesting that the CT genotype or T allele predis-
poses individuals toward POAG. In PACG, though the
angle architecture has been attributed for the initiation of
the disease however, other factors may also be involved.
On the other hand in POAG, in spite of normal anterior
angle structures, patients develop glaucomatous optic at-
rophy, indicating that multiple factors including genetic
ones may contribute towards its pathogenesis. This study
showed that MTHFR C677T might be one of those con-
tributing genetic factors for POAG in Saudi population.
This is the first report suggesting a significant associ-
ation of MTHFR C677T with POAG in a subset of Saudi
population. On the other hand lack of any association
between PACG and MTHFR C677T indicated that factors
other than MTHFR C677T could be important players in
susceptibility to PACG in our samples and future studies
involving different genes should be designed. Present
study suggested that the T allele of C677T imposed in-
creased risk for POAG in Saudi population, supporting
the hyperhomocysteinemia mediated death of RGC in
POAG. Our study also indicated that the distribution of
frequencies of genotypes and alleles of MTHFR C677T
polymorphism is not affected by gender of the patients
(Table 2). However, further studies should be conducted
in a larger cohort of males and females affected with
POAG to confirm it.
Conclusion
In conclusion the MTHFR C677T polymorphism is sig-
nificantly associated with susceptibility to POAG in our
population and can be a possible genetic marker for evalu-
ating the risk. however, further studies with multiple-
ethnic populations affected with POAG will strengthen
these findings.
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